Business
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.\n\n \n \n \n \n \n \n\n \nStifel Virtual Targeted Oncology ForumTuesday, April 16th, 2024 at 12:00 PM ET\nFireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Benjamin Burnett, Ph.D., Managing Director, Equity AnalystA live audio webcast of conference event, as permitted by conference host, will be available at the \"Investors/News and Events/Investor Calendar\" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.\nAbout IDEAYA BiosciencesIDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.\nForward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.\nInvestor and Media ContactIDEAYA BiosciencesAndres Ruiz BrisenoSenior Vice President, Head of Finance and Investor [email protected]\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-up...